Modernizing the 150-year-old microscope-based practice with digital innovation
CellNetix Pathology & Laboratories, one of the largest independent pathology service providers in the United States, is innovating its practice with digital pathology to advance its mission of excellence. In doing so, it will provide faster, more confident results and lay the foundation for artificial intelligence (AI)-driven pathology. CellNetix is working with Proscia®, a leading provider of digital and computational pathology solutions, to complete its transformation and digitize a portion of its 1 million glass slides per year.
Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024
Digital pathology is modernizing the microscope-based practice, driving a shift to high-resolution images that each contain over 1 billion pixels telling the story of a patient’s disease. Accelerated by a growing base of evidence, laboratories are adopting digital pathology to optimize routine operations, increase the confidence of decision making, enhance the pathologist experience, and unlock new insights with AI.
Recommended AI News: Keller Williams Deploys AI-Powered Ad Campaign Platform
“At CellNetix, we are mission-driven and pride ourselves on quality and delivering more precise results,” said Kathleen Fondren, CEO of CellNetix. “Adopting digital pathology is critical to furthering this aim. Proscia has established itself as a leading player in the space, and we are confident that working with the team will enable us to quickly realize the unprecedented potential of this innovation.”
In modernizing its practice with Proscia, CellNetix will achieve greater flexibility along with productivity and efficiency gains in its routine workflows. It will also streamline collaboration among the 60+ pathologists distributed across its regional network, broadening access to expertise. Looking ahead, CellNetix will remain on the forefront of pathology by paving the way to unlock new insights with AI and capitalize on the wealth of real-world data that it generates.
“CellNetix is ideally positioned to benefit from AI-powered digital pathology at scale,” said David West, Proscia’s CEO. “Its commitment to excellence is backed by a strong culture of innovation and collaboration. We look forward to seeing the impact of our efforts together, both immediately and as the promise of the technology continues to grow.”
Recommended AI News: ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial
With news, CellNetix joins the roster of leading laboratories and life sciences organizations that have turned to Proscia to accelerate their adoption of digital pathology. Proscia’s user base is made up of over 10,000 pathologists and scientists, including those from 14 of the top 20 pharmaceutical companies and leading anatomic pathology laboratories.
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.